

Index

- 1-800-DENTIST, 396
- 23andMe, 536
- 3rd Stone Design, 492–4
- 510(k)
 - abbreviated, 327
 - clinical data for, 541
 - cost, 331
 - de novo clearance, 326
 - meeting with FDA, 541
 - predicate device, 325, 538
 - review process and timing, 327
 - special, 327
 - strategies, 538
 - submission, 327
 - substantial equivalence, 325, 538
- Abbott Vascular, 471, 679
- Abele, John, 183, 635
- acceptance criteria, 51, 54–9, 219, 276
- AccessClosure, 646–8
- Accurant, 105–9, 239–45, 251, 280–1, 375, 449–54, 686–98, 809–16
- accountable care organizations, 158, 194, 359, 396, 398, 585, 636
- Accuray, Inc., 618, 629–33, 649–51
- Ackermann, Michael, 412–13, 486–9
- acquisition, 732, 754–5
- Acumen Fund, 762
- Adler, John, 629–33, 649–51
- Advanced Cardiovascular Systems (ACS), 442, 803
- Advanced Medical Technology Association (AdvaMed), 627, 649
- advocacy, 161, 595–6, 623, 649
- Affordable Care Act, 158, 351, 359, 585, 616, 652
- Africa, 10–12, 173–6, 384–7
- AirCare, 86
- Alamin, Todd, 438, 441–2, 737–9
- AliveCor, 396
- Allen, Michael, 361–2
- alternate pathways
 - acquisition, 793–5
 - building value toward, 797–800
 - build-to-buy, 794
 - lack of market access, 787
 - licensing, 788–9, 805–6
 - managing, 801–2
 - partnering, 789–93
 - preparing for, 800
 - returns, timing, and cost issues, 787–8
 - sale, 793–5
- America Invents Act, 288, 472
- America Society of Quality (ASQ), 553
- American Medical Association (AMA)
 - code of ethics, 65
 - CPT codes, 353–5
 - Relative Value Scale Update Committee, 583
- American Medical Systems (AMS), 55, 671
- anatomy, 119–20
- Angiotech, 666
- animal studies, 507–9
- Anner, John, 209
- Aravind Eye Hospital, 85
- Ardian, 126–30
- ArthroCare Corporation, 484, 496
- AstraZeneca, 789
- athenahealth, 627
- Atritech, 146
- Australia, 336–7, 688–90
- Azagury, Dan, 729
- Bakan, Greg, 531
- Bakken, Earl, 53
- barrier to entry, 458, 541, 645, 665, 669
- Bartlett, Rush, 420–3
- BATNA, 800–1
- Baxter, 673
- Beasley, Bill, 466
- Beggins, Scott, 341–4
- bench testing, 423–4, 491
- Bennett, Ian, 438–9, 737–9
- Bill & Melinda Gates Foundation, 758, 793
- BioInnovate, 87
- Biosense Technologies, 333
- Biosensors, 460
- BioTrace Medical, Inc., 771
- Blue Cross Blue Shield, 157, 358, 588
- Blue Cross Blue Shield Technology Evaluation Center (TEC), 360, 581, 589
- Boston Scientific, 552–3, 582–3, 640, 670, 679
- brainstorming
 - alternate approaches, 262–6
 - capturing ideas, 256, 261–2
 - choosing a facilitator, 258–9
 - framing the question, 252–3
 - ‘how might we’ questions, 252–3
 - IP ownership, 262
 - managing the session, 260–1
 - preparing for, 800
 - rules, 253–6
 - selecting participants, 257–8
 - use of artifacts, 255, 259
- Brazil, 32–5, 338
- bridge loan, 752
- Bruzzi, Mark, 87–8
- business model, 373
 - choosing, 374–6
 - defining characteristics, 374
 - factors affecting, 374
 - operationalizing, 400–1
 - validating, 400
- business model types
 - capital equipment, 383–4
 - disposable, 376–8
 - fee per use, 391
 - implantable, 380–1
 - over-the-counter, 394
 - physician-sell, 395
 - prescription, 394–5
 - reusable, 380
 - service, 387–8
 - subscription, 393–4
- business plan, 726–7
- business planning
 - executive summary, 734–7
 - importance of the team, 744–5
 - intrapreneurship, 745–6
- business strategies
 - disease management, 673–4
 - distribution play, 673
 - fast follower, 669–70
 - first mover, 669
 - information aggregator, 675
 - low-cost provider, 671–2
 - me-too, 670
 - niche play, 670–1
 - OEM/licensing, 678
 - overview, 669
 - partnering, 678–9
- Buxbaum, Darin, 262–3

Index

- C.R. Bard Inc., 562, 623
- Cahill, Colin, 438, 737–9
- Callaghan, Matt, 445–7
- Cambridge Antibody Technology, 789
- Cardica, Inc., 637, 705, 710–14
- Cardiocom, 397–400
- Caro, Elias, 758–61
- Carusi, Mike, 531, 546
- Casciaro, Gregory, 646–9, 651
- cash flow statement, 720–1
- cash requirements, 721, 740, 749, 773
- CE mark, 334–6, 547–8, 703
- Center for Biologics Evaluation & Research (CBER), 321, 536
- Center for Devices & Radiological Health (CDRH), 321, 323, 536–7, 580
- Center for Drug Evaluation & Research (CDER), 321, 536
- Centers for Medicare and Medicaid Services (CMS), 86, 157, 168, 320, 351, 506, 535, 574
- certificate of conformity, 335, 338
- Chang, John, 105–9, 239–45, 280–1, 449–54, 686–98, 809–16
- Chasmawala, Nish, 210–13
- Chaturvedi, Jagdish, 229
- Chehab, Eric, 236–8
- Chin, Albert, 795
- China, 14–17, 156, 159, 172, 304–5, 339–40, 367–8, 460, 672–3
- Ciel Medical, 729
- Cierra, Inc., 229–33
- Cigna, 581
- Circ Medtech, 762
- clinical studies
 - case control, 510–11
 - costs, 520–1
 - ethics, 522–3
 - first-in-human, 337, 509–10, 521
 - GCP, 522
 - geographic location, 521–2
 - GLP, 509–10
 - IACUC, 508
 - pre-clinical, 507–8
 - randomized, controlled, 511–12
 - registries, 510
 - trial nomenclature, 512
- clinical study goals
 - marketing, 507
 - regulatory, 506
 - reimbursement, 506
- clinical trial design
 - endpoints, 167, 513, 523
 - hypothesis, 512
 - IDE, 514–15, 537
 - informed consent, 517–18
 - investigators and center, 514
 - IRB, 515
 - patient enrollment, 516–17
 - size, 513
 - statistical design, 511–12
 - statistical power, 513–14
 - tips, 523
- clinical trial management
 - data management, 520
 - research site staff, 519
 - sponsor personnel, 519
- coding, *see* reimbursement in the US
- common stock, 751
- comparables analysis, 619, 723, 774
- competitive advantage
 - basis of competition, 679
 - capabilities, 664, 667–9
 - link to value proposition, 665
 - positional, 664–7
 - statement of, 682
- Computer Motion, 474–6
- Concentric Medical, 378–80
- concept map, 270, 272–4
- concept screening
 - clustering, 270–2
 - concept mapping, 272–4
 - eliminating ideas, 274–6
 - involving experts, 275–6
 - killer risks, 315–16, 344–5, 369–70, 401, 433
 - organizing ideas, 270–4
 - transition from ideation, 269–70
- concept selection, 433
 - alternatives to Pugh method, 441–2
 - getting to leading concepts, 434–5
 - Pugh method, 436–41
 - taking a structured approach, 435–6
- conflict of interest, 62, 465, 514–15, 522–3, 622, 802
- conformity assessment, 335
- Conor Medsystems, 771–3
- Consure Medical, 210–13
- contract research organization (CRO), 514
- contracting administration fee (CAF), 652
- copyright, 287
- Corbett, Jim, 680–2
- Cordis, *see* Johnson & Johnson
- core laboratories, 518
- CoreValve, 306–8
- Coridea, 56, 756
- cost-effectiveness, 147, 167, 367, 506, 589–90
- cost of goods sold (COGS), 703, 715
- cost projections
 - manufacturing costs, 715–17
 - operating expenses, 717–19
 - salary analysis, 715
- Coulter Foundation, 758–61
- Cowling, Don, 674–5
- Croce, Bob, 115–17
- Curtis, Gary, 378–80
- Cyberonics, 580
- cycle of care analysis, 69, 153–6, 605
- Cycle Technologies, 621
- Daktari Diagnostics, 173–6
- Dambkowski, Carl, 236–8
- data entry and monitoring, 518
- data safety and monitoring board, 519
- Davila, Liz, 391–3
- debt funding, 751
- Deem, Mark, 126–30, 136–7, 229–33, 265, 434
- depreciation, 720
- design controls, 556
- design validation, 556
- design verification, 556
- Devices for Vascular Intervention (DVI), 523–6
- Diasonics, 568–71
- digital health, *see* mobile health
- dilution, 771–2, 777
- direct sales models
 - interaction with marketing, 649
 - role of payers, 648
 - sales training, 648–9
 - selling process, 643–5
- discount rate, 774
- discounting terminal value, 774
- disease function, *see* mechanism of action
- disease progression, 121–2
- disease state research
 - anatomy, 119–21
 - clinical outcomes, 123–4
 - clinical presentation, 122–3
 - economic impact, 124
 - epidemiology, 118–19
 - optimizing, 124–6
 - pathophysiology, 121–2
 - physiology, 119–21
 - summarizing, 126
- Dollens, Ron, 627
- Donaldson, Krista, 209–10
- D-Rev, 88, 375–6, 758
- due diligence, 767–8, 800
- earnings statement, *see* income statement
- East Meets West Foundation, 209
- Edwards Lifesciences, 341–4

Ehrenreich, Kevin, 565–7	financing milestones, 722, 768–71	iRhythm, 312–15
elevator pitch, 729	first-in-human testing, 337, 509–10, 521	Johnson & Johnson, 115–17
Embrace, 758, 762	FitBit, 396	Kyphon, 657–61
empathy, 61, 72, 125	flow of money analysis, 153, 156–8, 605	Loma Vista Medical, 777–81
Emphasys Medical, 136–7, 527–30, 544–7	Fogarty, Thomas, 77, 251, 351, 457, 703	Medtronic, 52–3
Endogastric Solutions, 666	Food & Drug Administration (FDA)	Merck Serono, 674–5
Engelson, Eric, 229–33	background, 319–21	Metrika, Inc., 361–2
engineering, <i>see</i> R&D	clinical data from outside the US, 340–1	Mindray Medical, 672–3
epidemiology, 118	definition of medical device, 321	Miramar Labs, 606–11
equity funding, 750, 793	device classification, 321–3	Nanostim, 790–3
equity vs. debt, 750–1	fees, 330	NeoTract, Inc., 499–502
Ethicon, 668	GCP, 522	Northwestern University, 98–9
ethics	GLP, 509–10	Oculeve, 412–13, 486–9
AdvaMed code of ethics, 627, 649	GMP, 562	OEC Medical Systems, 568–71
AMA code of ethics, 65	HDE, 330	OneBreath, 445–7
conflict of interest, 62, 465, 514–15, 522–3, 622, 802	IDE, 329–30	Phoenix Medical Systems, 641–2
fiduciary duty, 63	MFUFMA, 330	Qualcomm Life, 675–8
IACUC, 508	mobile health, 331–4, 536	Radiology Partners, 388–91
in marketing, 627	QSR, 325, 552	Rapid Exchange, 803–5
in observations, 76–7	regulatory pathways, 323–9	Respironics, 79–81
informed consent, 517–18	Food, Drug, and Cosmetic Act, 320	Simpirica Spine, 737–9
overview, 62–5	Foundry, The, 56, 126–30, 136–7, 229–33, 265, 434, 527, 546, 756	Singapore-Stanford Biodesign, 277–8
principles, 64–5	Fox Hollow, 667	Spiracur, 463–4, 806–7
stakeholder analysis, 178–9	France, 19, 365–6	St. Francis Medical, 381–3
Tuskegee syphilis experiment, 63	freedom to operate, 289, 461–2	Stanford University team, 236–8, 262–3
ethnographic research, 72	Frenkel, Erica, 384–7	Sympara Medical, 565–7
Europe, 18–21, 87–8, 303, 306–8, 334–6, 341–4, 364–7, 547–9, 674–5	From the Field	The Foundry, 126–30, 136–7, 229–33
European Patent Office (EPO), 303	AccessClosure, 646–8	University of Cincinnati, 79–81
ev3, 679–82	Accuray, Inc., 629–33, 649–51	VentureHealth, 763–4
Evalve, Inc., 426–9	ACS, 442	Versant Ventures, 742–4
evergreening, 471	Ardian, 126–30	VISX, 391–3
exclusion criteria, 517	ArthroCare Corporation, 484	VNUS Medical, 597–601
exempt devices, 323–5	Cardica, Inc., 710–14	Vortex Medical, 795–7
exit event, <i>see</i> liquidity event	Cardiacom, 397–400	Vynca, 420–3
ExploraMed, 56, 59–61, 106, 756	Cierra, Inc., 229–33	Wing Tech Inc., 590–4
EyeNetra, 762	Concentric Medical, 378–80	functional blocks, 404, 413–15
	Consure Medical, 210–13	funding
	CoreValve, 306–8	choosing investors, 767
Facteau, William, 449–54, 686–98, 809–15	Coulter Foundation, 758–61	dilution, 771
Fahey, Brian, 423	Daktari Diagnostics, 173–6	due diligence, 767–8
Farley, Brian, 597–601	Diasonics, 568–71	equity vs. debt, 750–1
Federal Food and Drugs Act, 320	DoseRight Syringe Clip, 492–4	exit scenarios, 754–5
Fielding, Louie, 438, 737–9	DVI, 523–6	managing the process, 776–7
financial model	Edwards Lifesciences, 341–4	milestones, 768–71
cash balance and financing needs, 721	Emphasys Medical, 136–7, 527–30, 544–7	sources, 767
cash flows, 720–2	ev3, 679–82	stages/uses, 753–4
cost projections, 715–19	Evalve, Inc., 426–9	strategic considerations, 774–5
income statement, 719–20	ExploraMed, 59–61	term sheet, 775–6
market model, 707–10	Genomic Health, 206–9, 619–20	valuation, 771–5
operating plan, 705	Gradian Health Systems, 384–7	funding types
overview, 703–4	HiCARE LIMO, 82–3	debt, 751
profitability, 722	InnerPulse, 169–72	equity, 750
staffing plan, 705–7	Intuitive Surgical, 473–6	grants, 751

Index

- Gantt chart, 489, 731
Garrett, Kate, 729
Gelsinger, Jesse, 310, 516
Genomic Health, 206–9, 619–20
Germany, 18, 364–5
GI Dynamics, 666
Gifford, Hanson, 126–30, 136–7, 229–33, 527–30, 544–7
Given Imaging, 326
Glenn, Ben, 314
Glennon, Mike, 795–7
Global Harmonization Task Force (GHTF), 334
Gonzalez, Richard, 793
Good Clinical Practices (GCP), 522
Good Laboratory Practices (GLP), 509–10
Good Manufacturing Practices (GMP), 562
Gorsky, Alex, 636
Gradian Health Systems, 384–7
grant funding, 751
Green, David, 85
Green, Eric, 505
group purchasing organizations (GPO), 639
Guidant, 164, 621, 628, 669
Guo, Christine, 388–91

Hawkins, William, 53
Health Care Professionals Advisory Committee Review Board (HCPAC), 355
Health Insurance Portability and Accountability Act (HIPAA), 77
health maintenance organizations (HMOs), 359
HealthTap, 396
HiCARE LIMO, 82–3, 614
humanitarian device exemption (HDE), 330

IDEO, 253–4, 260
Imran, Mir, 94, 727, 749, 763–4
incidence, 118
inclusion criteria, 594
income statement, 719–20
Independent Payment Advisory Board (IPAB), 585
India, 23–6, 72, 82–3, 86–7, 156, 159, 161, 173, 210–13, 304, 339, 368–9, 375–6, 641–2
Indian Patent Office (IPO), 304
indications for use (IFU), 320, 327, 542
indirect sales and distribution models
 national distributors, 639
 specialty distributors, 639–40
 third-party partnerships, 640–2
informed consent, 330, 517–18
InHealth, 590
initial public offering (IPO), 732

InnAccel, 229
InnerPulse, 169–72, 196–7, 679
innovation notebook, 74, 308, 467
Institutional Animal Care and Use Committees (IACUC), 508
Institutional Review Board (IRB), 329, 515, 537
integrated delivery network (IDN), 158, 639
intellectual property (IP), 458
 documentation, 308–9
 freedom to operate, 289, 461–2
 international patenting, 302–6
 inventorship, 309
 law, 464
 patent searching, 289–95
 patentability, 288–9
 prior art, 289–91, 295
 provisional patent, 295–7
 public disclosure, 310–11, 467
 reduction to practice, 289
 utility patent, 297–302
intellectual property strategy
 defensive, 467–9
 freedom to operate, 461–2
 hiring legal help, 464–5
 international, 465–6
 litigation, 471–2
 managing a patent portfolio, 466–7
 offensive, 469–70
 patent coverage, 459–61
 timing, 470–1
Intermountain Health, 652
International Medical Device Regulators Forum (IMDRF), 334
International Organization for Standardization (ISO), 333, 562
International Searching Authority (ISA), 302
intrapreneurship, 723, 745–6
Intuitive Surgical, 400, 473–6, 540, 622
investigational device exemption (IDE), 329–30, 514–15
investors, *see* funding sources
Invivo Surgical Systems, 640
Ireland, 8, 87–8, 757
iRhythm, 312–15

Jacobs, Jamey, 800
Jaffe, Ross, 742–4
Janssen Labs, 756
Japan, 28–30, 337, 606–11
Johnson & Johnson, 115–17, 636, 670, 679, 756
Jones, Don, 675–8

Kaiser Permanente, 158, 162, 359, 652
Kamal, Ritu, 86–7

Kano model analysis, 416–19
Kelley, Tom, 248, 260, 416
Kelso, David, 98–9
key opinion leader (KOL), 95, 506, 595, 617, 627, 769
Khosla Impact, 762
Khosravi, Fred, 646
Knappe, Brett, 397–400
Kumar, Uday, 312–15
Kumar, V. Sashi, 641–2
Kyphon, 548, 657–61, 664, 669, 682–4

Lake Region Corporation, 678
Lam Wang, Sharon, 239–45, 449–54, 686–98, 809–16
Lamson, Ted, 59, 499–502
Lebeau, Guy, 162, 480
lexicographer, 461
licensing, 641, 678, 754
Lifescan, 640
Linehan, John, 590, 593
liquidity event, 732, 766, 769, 771, 826
local coverage determination (LCD), 353, 578
Loma Vista Medical, 623, 777–81
Lu, Yoh-Chie, 460

Makhzoumi, Mohamad, 388–91
Makower, Josh, 59–61, 105–9, 239–45, 280–1, 449–54, 686–98, 809–16
market analysis
 choosing target market, 201–3
 global considerations, 209–10
 landscaping the market, 183–6
 market development, 618
 pitfalls, 205–6
 segmenting the market, 186–201
market model
 bottom-up, 192, 643, 708–10
 top-down, 191–4, 707–8
marketing
 communication strategy, 623–7
 market research, 605–6, 611
 public relations strategy, 627–9
 value proposition, 611–18
marketing mix
 positioning, 622–3
 pricing, 619–22
 product/service mix, 618–19
 promotion, 623–9
master resellers, 640
May, Allan, 568–71, 790–3
McCutcheon, John, 527–30, 544–7
McGlynn, Casey, 765
MDStart, 756

mechanism of action, 100, 146, 235, 272	observations, 71–6	patenting outside the US
Medicaid, 157	overview, 67–8	China, 304–5
Medical Device Amendments Act, 320	value, 81–6	India, 304
medical device reporting (MDR), 559	needs selection	Patent Cooperation Treaty (PCT), 302–3
Medical Devices Directive (MDD), 334	assigning ratings, 220–2	PATH, 793
medical necessity, 167	choosing factors, 217–21	pathophysiology, 121
Medicare, 85, 157, 165, 351	combining values, 222–5	Patient Centered Outcomes Research Institute (PCORI), 585
Medinol, 640	overview, 215–17	Perclose, 426
Medtronic, 52–3, 129, 306–8, 397–400, 583, 640, 679	selecting needs, 224–6	Percusurge, Inc., 548
Merck Serono, 674–5	specification, 233–8	Perkins, Rodney, 546, 740
Metrika, Inc., 361–2, 575	validation, 226–7	personal inventory
Mexico, 32–5, 486–9, 504–5	NeilMed, 653	mission, 51–4
Mindray Medical, 672–3	Neodyne Biosciences, 465	relevance to alternate pathways, 787
Miramar Labs, 606–11	NeoTract, Inc., 61, 499–502	strengths and weaknesses, 54
Miros, Robert, 492–4	Newell, Bob, 710	Pfizer, 665, 678
mission statement, 51–4	Niveus Medical, 423	Phoenix Medical Systems, 376, 641–2
mobile health, 134, 163, 202, 331–4, 395–7, 536, 704	non-disclosure agreement (NDA), 311–12, 800	Phoon, Justin, 277–8
Mobile Medic, 758	Northwestern University, 98–9	physiology, 119
Moll, Fred, 473–6	notice of allowance, 301	Pietzsch, Jan, 590–4
Mulago Foundation, 758	notified bodies, 335	Pinto, Moshe, 183, 463–4, 806–7
	null hypothesis, 513	pitch
	observation	components, 728–33
	conducting, 72–4	considerations, 727–8
	documenting, 74–6	developing, 733–4
	ethics, 76–7	funding, 739–42
	preparing for, 68–71	Plain, Hank, 528, 546
	observer effect, 73	Popovits, Kim, 208, 620
	Ocejo, Santiago, 504	Porter’s five forces, 195
	Oculeve, 412–13, 486–9	Practice Fusion, 397
	OEC Medical Systems, 568–71	pre-amendment devices, 325
	office action (OA), 301, 460	predicate device, 538, 541
	Office for Human Research Protections (OHRP), 516	preferred provider organizations (PPOs), 359
	Office of Combination Products (OCP), 321, 536	preferred stock, 751
	Office of Device Evaluation (ODE), 321	premarket approval (PMA)
	Office of In Vitro Diagnostics and Radiological Health (OIR), 321, 323	cost, 331
	Office of Initial Patent Examination (OIPE), 301	meeting with FDA, 543
	Office of Technology Licensing (OTL), 465, 806	modular, 329
	off-label use, 547	post-approval requirements, 543
	One Medical, 394	product development protocol (PDP), 329
	OneBreath, 445–7	review process and timing, 329
	operating expenses (OpEx), 715	strategies, 543
	option pool, 775	submission, 328–9
	Orthopaedic Implant Company, 615	traditional, 328
	out-of-pocket payment, 156, 159, 360	prevalence, 118
		pricing
	Palmaz, Julio, 251, 308	bundled, 621
	Papanek, Julie, 236–8	differential, 620
	Papiernik, Antoine, 306–8	establishing a baseline, 619
	partnering, 678–9	gainsharing, 621
	Patent Cooperation Treat (PCT), 302–3	link to reimbursement, 586
	patent litigation, 392	pay-for-performance, 622
		value-based, 586, 619

Index

- prior art, 295, 302, 461
- Privitera, Mary Bath, 79–81
- professional societies, 65, 163, 579, 628
- profitability, 722
- proof-of-concept, 479, 482
- Propeller Health, 653–5
- protected health information (PHI), 77
- prototyping
 - in-house vs. outsourcing, 425–6
 - models, 409–11
 - testing, 417–25
 - timing, 416
 - tips, 429–30
- prototyping guidelines
 - choosing model, 409–11
 - defining requirements, 415–16
 - identifying functional blocks, 413–14
 - identifying questions, 407–9
 - understanding what is known, 414–15
- proxy company analysis, 723
- public relations strategy, 627–9
- Pugh method for concept selection
 - assigning scores and ranking concepts, 440
 - confirming concepts and choose a baseline, 439
 - identifying user and design requirements, 437
 - iterative nature of, 436
 - overview, 436
 - weighting user and design requirements, 437
- Pulmonx, 546
- Qualcomm Life, 675–8
- quality assurance (QA), 553
- quality control (QC), 553
- quality management system (QMS)
 - CAPA, 559
 - design controls, 556
 - equipment and facility controls, 559
 - implementing, 560–2
 - ISO 13485, 562
 - management controls, 555–6
 - material controls, 560
 - P&PC, 556–9
 - QSIT, 567
 - QSR, 552, 562
 - QSR vs. ISO, 562–4
 - records, documents, and change controls, 560
- quality system audits, 567–8
- R&D milestones, 481–2
- R&D plan
 - activities, 490–2
 - engineering resources, 496–8
 - link to strategy, 480–1
 - personnel, 494–6
 - timelines, 480–1
- R&D technical challenges, 482–4
- Radiology Partners, 388–91
- Rainbow Medical, 756
- Raje, Pulin, 82–3
- Rao, Geetha, 332
- Rapid Exchange, 803–5
- reduction to practice, 289
- referral patterns, 154
- regulation in the US, *see* Food & Drug Administration (FDA)
- regulation outside the US
 - Australia, 336–7
 - Brazil, 338
 - Canada, 336
 - China, 339–40
 - Europe, 334–6
 - India, 339
 - Japan, 337
 - Russia, 338–9
- regulatory strategy
 - 510(k) strategies, 541
 - 510(k) vs. PMA, 538
 - global strategies, 547–9
 - IDE strategies, 537–8
 - link to reimbursement, 535
 - off-label use, 547
 - premarket approval strategies, 541–3
- reimbursement in the US
 - background, 352
 - coding, 352–3, 574–8
 - coverage, 353, 578–81
 - hospital inpatient reimbursement, 357–8
 - hospital outpatient reimbursement, 357–8
 - payment, 353–5, 581–5
 - physician reimbursement, 355–7
 - private payers, 358–60
 - self-pay, 360
- reimbursement outside the US
 - China, 367–8
 - France, 365–6
 - Germany, 364–5
 - India, 368–9
 - overview, 363–4
 - United Kingdom, 366–7
- reimbursement strategy
 - advocacy, 595–6
 - competitors and proxies, 586
 - design of clinical trials, 588
 - developing, 585–6
 - disseminating economic evidence, 594
 - dossier, 594
 - expanding reimbursement, 574–85
 - parallel review, 580
 - payer advisory boards, 596
 - payer segmentation, 586–7
 - payer value proposition, 588
 - pricing, 586
 - reimbursement support, 601
- Relative Value Scale Update Committee (RUC), 583
- relative value units (RVUs), 356, 583
- Resource Based Relative Value System (RBRVS), 355
- Respira Design, 504–5
- Respiroics, 79–81
- Rock Health, 756
- Rodriguez, Bill, 173–6
- royalty-backed loans, 752
- Rudy, Steve, 384–7
- Russia, 18, 338–9
- Sadler, Joel, 72
- Sainz, Maria, 379
- sales and distribution models
 - choosing, 655–60
 - direct, 642–51
 - hybrid, 651–2
 - indirect, 639–42
 - overview, 636–9
 - strategic considerations, 652–5
- Satiety, 666
- SciMed, 670
- Scott, Randy, 206–8
- self-pay, *see* out-of-pocket payment
- SG&A expenses, 719–20
- Sharma, Amit, 210–13, 261
- Shelhigh Inc., 562
- Shenasa, Jafar, 332
- Sherman Act, 673
- Sidow, Kevin, 381–3, 657
- Simpirica Spine, 438, 441–2, 737–9
- Simpson, Carl, 251, 442, 804
- Simpson, John, 523–6, 803
- simulated use testing, 423, 491
- Singapore-Stanford Biodesign, 277
- solution analysis
 - clinical profile, 141–4
 - economic profile, 144–5
 - emerging profile, 145–6
 - landscape, 146–9
 - overview, 138–41
 - utilization profile, 145

solution bias, 97, 275	Surmodics, 678	selling, 644
solution gaps, 135, 147	SWOT analysis, 195–7	value signposts
Spiracur, 185, 463–4, 806–7	Sympara Medical, 565–7	budget-based, 3, 85
Sproxil, Inc., 762		practice-based, 3, 82
St. Francis Medical, 381–3, 656	Talmadge, Karen, 657–61	Van Sickle, David, 653–5
St. Goar, Fred, 426–9	Tenet, 652	Van Wert, Ryan, 420–3
St. Jude Medical, 583, 758, 790–3	Teo, Pearline, 277–8	Van, Sue, 758–61
Stack, Richard, 153, 183, 196–7	term sheet, 775–6	Venkataswamy, Govindappa, 85
staffing ratios, 706	terminal value, 774	venture debt, 752
stakeholder analysis	testing continuum, 417, 479, 507	VentureHealth, 763–4
cycle of care, 153–6	Thapliyal, Hira, 484	Versant Ventures, 742–4
ethics, 178–9	The Innovation Factory, 56, 756	VISX, 391–3
flow of money, 153, 156–8	Thornton, Troy, 426–9	VNUS Medical, 597–601
output, 177	Tilson, Alex, 777–81	Vortex Medical, 795–7
stakeholder interests	tissue testing, 424–5, 507	Vynca, 420–3
facilities, 164–7	trade secrets, 287	
government, 172–6	trademark, 287	Wang, Frank, 420–3
patients, 159–62	TRIZ, 266	warrant, 773
payers, 167–9		Wasden, Chris, 616
physicians, 162–4	US healthcare financing system, 157	WebMD, 397
Stanford-India Biodesign, 83, 86, 210, 227	US Patent and Trademark Office (USPTO), 287, 459	Welltok, 393
Stark Law, 622	US Surgical, 668	Whitney, Rich, 388–91
Starling, Bill, 196–7	United Kingdom, 19, 366–7, 674–5	Will, Allan, 523–6
StartX, 756	University of Cincinnati, 79–81	Wilson Greatbatch, 678
State Intellectual Property Office (SIPO), 304	user testing, 417–20	Wing Tech Inc., 590–4
statistical power, 511, 513	U-Systems, 628	Winlo, Michael, 185–6, 194, 200
strategic focus		Wohl, Barry, 505
acceptance criteria, 54–9	value, 1–4	World Intellectual Property Organization (WIPO), 302
ethics, 62–5	value analysis committee, 162, 636	
external factors, 54	value estimate, 3, 196, 201, 612	Yock, Paul, 803–5
global considerations, 61–2	value exploration, 3, 81–6	
personal inventory, 51–4	value proposition, 4	Zang, Xiangwen, 86
Stryker, 666, 673	developing, 611–18	Zimmer, 666
substantially equivalent (SE) determination, 327	link to competitive advantage, 664–5	ZocDoc, 396
superseding need, 94	payer-specific, 588–90	Zoromski, Darrell, 606–11
	physician-specific, 595	